UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference

Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company focused on innovative solutions for urothelial and specialty cancers, will participate in the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 10:30 AM Eastern Time. The panel discussion will be available via live webcast on their website, with a replay accessible for 30 days. UroGen's proprietary RTGel™ technology enhances drug delivery for better treatment outcomes, particularly for low-grade non-muscle invasive bladder cancer. For more information, visit www.urogen.com.

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions to treat urothelial and specialty cancers, today announced that it will participate in a panel discussion at the upcoming virtual Cowen 42^nd Annual Healthcare Conference on March 8, 2022 at 10:30am Eastern Time.

A live webcast of the panel will be available on the Investors & Media section of UroGen’s website at www.urogen.com. A replay of the webcast will be available on the Company’s website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product and the investigational treatment UGN-102 (mitomycin) for intravesical solution in development for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005334/en/

INVESTOR CONTACT:

Vincent Perrone

Senior Director, Investor Relations

vincent.perrone@urogen.com

609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano

Director, Corporate Communications

cindy.romano@urogen.com

609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.

FAQ

When will UroGen Pharma participate in the Cowen 42nd Annual Healthcare Conference?

UroGen Pharma will participate in the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 10:30 AM Eastern Time.

How can I watch the UroGen Pharma conference panel discussion?

The panel discussion will be available via live webcast on UroGen's Investors & Media section of their website.

What is the main focus of UroGen Pharma's technology?

UroGen Pharma's RTGel™ technology aims to improve therapeutic profiles of drugs, particularly for treating urothelial and specialty cancers.

What is UGN-102 developed by UroGen Pharma?

UGN-102 is an investigational treatment for patients with low-grade non-muscle invasive bladder cancer, designed to ablate tumors non-surgically.

Where is UroGen Pharma located?

UroGen Pharma is headquartered in Princeton, NJ, with operations in Israel.